Indeed, treatment of tumor-bearing mice with a CCR-5 or a CSFR1-targeted tyrosine kinase antagonist improved the efficacy of anti-PD1 treatment and impeded tumor growth by significantly decreasing the percentage of intra-tumoral MDSCs [115,116]. The gene discussed is CCR5; the disease is neoplasm.